Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen

Biochimica et Biophysica Acta - Biomembranes

Volumn 1468, Issue 1-2, 2000, Pages 31-40

  Oja, Conrad ^a   Tardi, Paul ^b   Schutze Redelmeier, Marie Paule ^b   Cullis, Pieter R ^a,c  

^a Dept Biochem Molec Biol U   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Inex Pharmaceuticals Corporation   (Canada)

Author keywords

Conjugation; Doxorubicin; Immune response; Liposome; Ovalbumin

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; OVALBUMIN; PHOSPHOLIPID;

ARTICLE; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; PRIORITY JOURNAL;

ANIMAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; OVALBUMIN; PROTEOLIPIDS; SUPPORT, NON-U.S. GOV'T;

EID: 0034730566     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(00)00178-4     Document Type: Article

References (40)

1. Aragnol D., Leserman L.D. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA. 83:1986;2699-2703.
2. Debs R.J., Heath T.D., Papahadjopoulos D. Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration. Biochim. Biophys. Acta. 901:1987;183-190.
3. Loughrey H.C., Ferraretto A., Cannon A., Acerbis G., Sudati F., Bottiroli G., Masserina M., Soria M.R. Characterization of biotinylated liposomes for in vivo targeting applications. FEBS Lett. 332:1993;183-188.
4. Klibanov A.L., Marulama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:1990;235-237.
5. Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 284:1991;263-266.
6. Longman S.A., Cullis P.R., Choi L., DeJong G., Bally M.B. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother. Pharmacol. 36:1995;91-101.
7. Suzuki S., Uno S., Fukuda Y., Aoki Y., Masuko T., Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer. 72:1995;663-668.
8. Goren D., Horowitz A.T., Zalipsky S., Woodle M.C., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer. 74:1996;1749-1756.
9. Vingerhoeds M.H., Steerenberg P.A., Hendriks J.J.G.W., Dekkar L.C., VanHoesel Q.G.C.M., Crommelin D.J.A., Storm G. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer. 74:1996;1023-1029.
10. G. Gregoriadis, The carrier potential of liposomes in biology and medicine, New Engl. J. Med. 295 (1976) 704-710 and 765-770.
11. Therien H.M., Shahum E., Fortin A. Liposome adjuvanticity: influence of dose and protein:lipid ratio on the humoral response to encapsulated and surface-linked antigen. Cell. Immunol. 136:1991;402-413.
12. Shahum E., Therien H.M. Correlation between in vitro and in vivo behaviour of liposomal antigens. Vaccine. 12:1994;1125-1131.
13. Shek P.N., Lopez N.G., Heath T.D. Immune response mediated by liposome-associated protein antigens. IV. Modulation of antibody formation by vesicle-encapsulated methotrexate. Immunology. 57:1986;153-157.
14. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods. 174:1994;83-93.
15. Tardi P.G., Swartz E.N., Harasym T.O., Cullis P.R., Bally M.B. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J. Immunol. Methods. 210:1997;137-148.
16. Shek P.N., Lukovich S. The role of macrophages in promoting the antibody response mediated by liposome-associated protein antigens. Immunol. Lett. 5:1982;305-309.
17. Su D., Van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen. Immunology. 66:1989;466-470.
18. Szoka F.C. Jr. The macrophage as the principal antigen-presenting cell for liposome-encapsulated antigen. Res. Immunol. 143:1992;186-188.
19. Daemen T., Hofstede G., Kate M.T.T., Bakker-Woudenberg I.A.J.M., Scherphof G. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer. 61:1995;716-721.
20. Daemen T., Regts J., Meesters M., Kate M.T.T., Bakker-Woudenberg I.A.J.M., Scherphof G.L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Controlled Release. 44:1997;1-9.
21. Tadakuma T., Yasuda T., Kinsky S.C., Pierce C.W. The effect of epitope density on the in vitro immunogenicity of hapten-sensitized liposomal model membranes. J. Immunol. 124:1980;2175-2179.
22. Walden P., Nagy Z.A., Klein J. Major histocompatibility complex-restricted and unrestricted activation of helper T cell lines by liposome-bound antigens. J. Mol. Cell Immunol. 2:1986;191-197.
23. Walden P., Nagy Z.A., Klein J. Antigen presentation by liposomes: inhibition with antibodies. Eur. J. Immunol. 16:1986;717-720.
24. Dal Monte P., Szoka F.C. Jr. Antigen presentation by B cells and macrophages of cytochrome c and its antigenic fragment when conjugated to the surface of liposomes. Vaccine. 7:1989;401-408.
25. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65.
26. 3H]cholesteryl oleoyl ether in cultured fibroblasts and intact rat. FEBS Lett. 111:1980;104-106.
27. Halperin G., Stein O., Stein Y. Synthesis of ether analogs of lipoprotein lipids and their biological applications. Methods Enzymol. 129:1986;816-848.
28. Derksen J.T.P., Morselt H.W.M., Scherphof G.L. Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta. 931:1987;33-40.
29. Fiske C.H., Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66:1925;375-400.
30. Loughrey H.C., Choi L.S., Cullis P.R., Bally M.B. Optimized procedures for the coupling of proteins to liposomes. J. Immunol. Methods. 132:1990;25-35.
31. Loughrey H.C., Wong K.F., Choi L.S., Cullis P.R., Bally M.B. Protein-liposome conjugates with defined size distributions. Biochim. Biophys. Acta. 1028:1990;73-81.
32. Mayer L.D., Bally M.B., Hope M.J., Cullis P.R. Techniques for encapsulating bioactive agents into liposomes. Chem. Phys. Lipids. 40:1986;333-345.
33. Mayer L.D., Bally M.B., Cullis P.R. Strategies for optimizing liposomal doxorubicin. J. Liposome Res. 1:1990;463-480.
34. Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., Emerman J.T. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 53:1990;183-190.
35. Roerdink F., Dijkstra J., Hartman G., Bolscher B., Scherphof G. The involvement of parenchymal, Kupffer and endothelial liver cells in the hepatic uptake of intravenously injected liposomes. Effects of lanthanum and gadolinium salts. Biochim. Biophys. Acta. 677:1981;79-89.
36. Poste G., Bucana C., Raz A., Bugelski P., Kirsh R., Fidler I.J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 42:1982;1412-1422.
37. Albert M., Sauter B., Bhardway N. Dendritic cells acquire antigen specific from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
38. Ronchetti A., Rovere P., Iezzi G., Galati G., Heltai S., Protti M. Pia, Garancini M., Maqnfredi A., Rugarli C., Bellone M. Immunogenicity of apoptotic cells in vivo role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163:1999;130-136.
39. Voo R., Herrman M., Roth E., Stach C., Kalder J., Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 390:1997;350-351.
40. Fadok V., Bratton D., Konowal A., Freed P., Westcott J., Henson P. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101:1998;890-898.